Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Apr-Dec Sales Drop 1.2% due to Impact of Great East Japan Earthquake: MTPC
February 1, 2012
- Shared Awareness of Goals Needed in Industry-Academia Collaborations: Dr Teshirogi of Shionogi
February 1, 2012
- Patient Enrollment for All-case PMS for Imusera, Telavic Making Steady Progress: MTPC
February 1, 2012
- Mochida Pharmaceutical Sees Double-Digit Growth in Apr-Dec on Growth of Epadel
January 31, 2012
- DSP to Set Up New Chemical Research Building at Osaka Research Center
January 31, 2012
- Apr-Dec Sales Drop 8.5% due to Slump of US Subsidiary: Shionogi
January 31, 2012
- Shionogi to Set Up Development Site in Europe to Accelerate Global Development
January 31, 2012
- Takeda Initiates Domestic PIII Clinical Trials for New Prostate Cancer Drug, TAK-700
January 30, 2012
- Medisa Shinyaku’s Kyushu Plant Transfers to Sawai
January 30, 2012
- US Sales of Abilify in 2011 Post $3.96 Billion: Otsuka HD
January 30, 2012
- CMIC Chairman Nakamura Keen to “Create Profit-Generating Mechanism” for Ultra-Orphan Drugs
January 27, 2012
- Sawai Refrains from Promotion of Aricept Generics due to Tough Price Competition
January 27, 2012
- Baxter of US to Begin New Global PIII Trial of Immunoglobulin for the Treatment of Alzheimer’s Disease
January 27, 2012
- Novartis Eyes Market Penetration with pNET Indication for Afinitor, Prolonged QOL for Patients
January 26, 2012
- Abbott Sets Up New Unit With MRs Specializing in CNS, Anesthetics for Luvox Transfer
January 26, 2012
- Nippon Kayaku’s Nambu Stresses Need for Collaboration between Medium-Sized Companies in Biosimilars
January 26, 2012
- Taiyo, Teva-Kowa to Establish Teva Pharma Japan in April, with 7 Branches, 29 Sales Offices Nationwide
January 26, 2012
- 301 MSs from Medipal HD Pass 18th MR Examination
January 26, 2012
- Achievement of SVR12 with DAA-only Combination Therapy Possible in Hepatitis C: BMS
January 26, 2012
- Toho HD Upwardly Revises FY2012 Earnings Forecast Expecting Boosted Sales, Profits
January 25, 2012
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…